EDGAR Online

VIROPHARMA INC

FORM 8-K
(Current report filing)

Filed 06/22/12 for the Period Ending 06/20/12

Address	730 STOCKTON DRIVE EXTON, PA 19341
Telephone	6104587300
CIK	0000946840
Symbol	VPHM
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online
http://www.edgar-online.com
© Copyright 2012, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): June 20, 2012

V IRO P HARMA I NCORPORATED
(Exact Name of Registrant as Specified in its Charter)

DELAWARE (State or Other Jurisdiction of Incorporation or Organization)	**0-021699** (Commission File Number)	**23-2789550** (I.R.S. Employer Identification Number)

730 STOCKTON DRIVE, EXTON, PENNSYLVANIA
(Address of Principal Executive Offices)

19341
(Zip Code)

(610) 458-7300
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As of June 20, 2012, Richard Morris will no longer serve as the Chief Accounting Officer of ViroPharma Incorporated, a Delaware corporation (the "Company"). Mr. Morris will remain with the Company as Vice President, Financial Planning and Strategic Analysis. The Company is actively searching to fill Mr. Morris's former role. In the interim, Charles Rowland, our Chief Financial Officer, will assume the role of Principal Financial and Accounting Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIRO PHARMA INCORPORATED

Date: June 22, 2012

By: /s/ J. Peter Wolf
J. Peter Wolf
Vice President, General Counsel and Secretary